Market is being manipulated higher as big money is pulling out ahead of a looming huge crash. That is what I see. (8/2/12)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like the looks of UITA myself college.
Yep rain..UITA something is up.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49048535
UITA nice college....Check this quick DD I put together.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49048535
Hey jt....Looks good.
UITA on hot watch today for sure.
UITA should be very strong today after yesterday's volume surge. GLTY
UITA ready for pop. Yesterday's volume doesn't lie.
EFIR news machine is rolling now. WEEEEEEEEEEEEEEEEEEEEEEE
Put me down for UITA today also Pink.
I for one love that we are actually getting info and PRs. This company hasn't always done that in a timely way. I look for strong things in the days to come. Tomorrow will see a pullback sure with the flippers and daytraders. Might not be a bad idea to lock in some profit and then load again on the dips. This one has great short and long term potential IMHO.
GLTY
Check UITA for a pop too.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49048535
Ha ha.....Like ur pic too. EFIR gonna go parabolic tomorrow man. We tried to tell em. :)
UITA looking really good for tomorrow. Check this quick DD compilation.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49048535
Hey Momo, just a quick compilation for you that makes me really like this one:
Excerpts from Feb 22 news: Utilicraft Aerospace Plans Flight-Test Study for Its Humanitarian Aircraft Development Program
ALBUQUERQUE, N.M., Feb 22, 2010 (BUSINESS WIRE) -- Utilicraft Aerospace Industries, Inc. (PINK SHEETS: UITA) announced today that it plans to initiate an in-house flight test program to further study the STOL utility market for its planned humanitarian relief aircraft development.
As the Company commences its flight test study program, expect regular release updates on further on-going developments.
We are all quite aware of the ongoing need for humanitarian relief. What is not to like about that?
Excerpts from Feb 8 news: Utilicraft Aerospace Industries Announces Business Development Private Placement
ALBUQUERQUE, N.M., Feb 08, 2010 (BUSINESS WIRE) -- Utilicraft Aerospace Industries, Inc. (Symbol: UITA.PK) announced today a $780K Private Placement Memorandum to raise new capital to take the Company in a new direction as described below.
As part of the new direction of UITA as an aerospace technology development holding company, the Company is reviewing strategic acquisition possibilities - or the in-house development - of a Light Observation Aircraft (LOA) program intended for disaster "emergency first response" missions.
It is to be a "rapid deployment" observation aircraft, equipped with the latest electronic surveillance equipment for rapidly detecting life-signs of disaster victims trapped in debris or damaged structures over a wide search area in the shortest amount of time - as a search and rescue (SAR) airborne platform electronically transmitting coordinates to and from ground rescue teams.
This tells us that this company is headed in right direction and people believe in their product.
Plus, per their 8-k from Jan 22, they had a recent acquisition and are looking to be uplisted soon and be fully current and reporting.
On January 21, 2010, Utilicraft Aerospace Industries, Inc. (the "Company"), with board approval, entered into a Subsidiary Acquisition Agreement with United Aircraft Development Partners, Inc. ("UADP") pursuant to which the Company issued 103,250,000 shares of its common stock in exchange for a 100% ownership of UADP. See Exhibit 10.1.
The Board of Directors decision to acquire United Aircraft Development was based upon its contributing to the consolidated company, a Memorandum of Understanding that United Aircraft Development had previously entered into to merge with an existing operating aerospace company. It is the Utilicraft Board's intention to build a stronger balance sheet, and to create operating activities with operating histories which will help Utilicraft Aerospace to become a fully reporting company on a higher stock trading exchange with increased shareholder value.
Trust me.....Plenty to like here.
Masked, UITA is a very nice one. Really like what I see.
Excerpts from Feb 22 news: Utilicraft Aerospace Plans Flight-Test Study for Its Humanitarian Aircraft Development Program
ALBUQUERQUE, N.M., Feb 22, 2010 (BUSINESS WIRE) -- Utilicraft Aerospace Industries, Inc. (PINK SHEETS: UITA) announced today that it plans to initiate an in-house flight test program to further study the STOL utility market for its planned humanitarian relief aircraft development.
As the Company commences its flight test study program, expect regular release updates on further on-going developments.
We are all quite aware of the ongoing need for humanitarian relief. What is not to like about that?
Excerpts from Feb 8 news: Utilicraft Aerospace Industries Announces Business Development Private Placement
ALBUQUERQUE, N.M., Feb 08, 2010 (BUSINESS WIRE) -- Utilicraft Aerospace Industries, Inc. (Symbol: UITA.PK) announced today a $780K Private Placement Memorandum to raise new capital to take the Company in a new direction as described below.
As part of the new direction of UITA as an aerospace technology development holding company, the Company is reviewing strategic acquisition possibilities - or the in-house development - of a Light Observation Aircraft (LOA) program intended for disaster "emergency first response" missions.
It is to be a "rapid deployment" observation aircraft, equipped with the latest electronic surveillance equipment for rapidly detecting life-signs of disaster victims trapped in debris or damaged structures over a wide search area in the shortest amount of time - as a search and rescue (SAR) airborne platform electronically transmitting coordinates to and from ground rescue teams.
This tells us that this company is headed in right direction and people believe in their product.
Plus, per their 8-k from Jan 22, they had a recent acquisition and are looking to be uplisted soon and be fully current and reporting.
On January 21, 2010, Utilicraft Aerospace Industries, Inc. (the "Company"), with board approval, entered into a Subsidiary Acquisition Agreement with United Aircraft Development Partners, Inc. ("UADP") pursuant to which the Company issued 103,250,000 shares of its common stock in exchange for a 100% ownership of UADP. See Exhibit 10.1.
The Board of Directors decision to acquire United Aircraft Development was based upon its contributing to the consolidated company, a Memorandum of Understanding that United Aircraft Development had previously entered into to merge with an existing operating aerospace company. It is the Utilicraft Board's intention to build a stronger balance sheet, and to create operating activities with operating histories which will help Utilicraft Aerospace to become a fully reporting company on a higher stock trading exchange with increased shareholder value.
Trust me.....Plenty to like here.
Rain UITA is next and here is why.
Excerpts from Feb 22 news: Utilicraft Aerospace Plans Flight-Test Study for Its Humanitarian Aircraft Development Program
ALBUQUERQUE, N.M., Feb 22, 2010 (BUSINESS WIRE) -- Utilicraft Aerospace Industries, Inc. (PINK SHEETS: UITA) announced today that it plans to initiate an in-house flight test program to further study the STOL utility market for its planned humanitarian relief aircraft development.
As the Company commences its flight test study program, expect regular release updates on further on-going developments.
We are all quite aware of the ongoing need for humanitarian relief. What is not to like about that?
Excerpts from Feb 8 news: Utilicraft Aerospace Industries Announces Business Development Private Placement
ALBUQUERQUE, N.M., Feb 08, 2010 (BUSINESS WIRE) -- Utilicraft Aerospace Industries, Inc. (Symbol: UITA.PK) announced today a $780K Private Placement Memorandum to raise new capital to take the Company in a new direction as described below.
As part of the new direction of UITA as an aerospace technology development holding company, the Company is reviewing strategic acquisition possibilities - or the in-house development - of a Light Observation Aircraft (LOA) program intended for disaster "emergency first response" missions.
It is to be a "rapid deployment" observation aircraft, equipped with the latest electronic surveillance equipment for rapidly detecting life-signs of disaster victims trapped in debris or damaged structures over a wide search area in the shortest amount of time - as a search and rescue (SAR) airborne platform electronically transmitting coordinates to and from ground rescue teams.
This tells us that this company is headed in right direction and people believe in their product.
Plus, per their 8-k from Jan 22, they had a recent acquisition and are looking to be uplisted soon and be fully current and reporting.
On January 21, 2010, Utilicraft Aerospace Industries, Inc. (the "Company"), with board approval, entered into a Subsidiary Acquisition Agreement with United Aircraft Development Partners, Inc. ("UADP") pursuant to which the Company issued 103,250,000 shares of its common stock in exchange for a 100% ownership of UADP. See Exhibit 10.1.
The Board of Directors decision to acquire United Aircraft Development was based upon its contributing to the consolidated company, a Memorandum of Understanding that United Aircraft Development had previously entered into to merge with an existing operating aerospace company. It is the Utilicraft Board's intention to build a stronger balance sheet, and to create operating activities with operating histories which will help Utilicraft Aerospace to become a fully reporting company on a higher stock trading exchange with increased shareholder value.
Trust me.....Plenty to like here.
My thought is blah blah blah....LOL
All that stuff gets confusing. Looks good though. Some saying .10 target now.
EFIR very nice man. Glad I grabbed @ 008 last week. Congrats.
My summary: alot to read. :)
EFIR 10-k is out now.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6892694
UITA I like a lot. Looked good today. Seems like something may be up there.
UITA man. Nice. Volume before price. Great action today.
How can you say EFIR snuck up on you? I was tellin ya @ 008 last week. Come on man. :)
EFIR alerted here @ 008 for those that were listening....CONGRATS.
Wow...lots of new names around here now. LOL
So long as ur watching something green right? LOL
What is up Lot?
News out this am:
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS)
Follows Highly Successful Oral Presentation at the 2010 American Professional Wound Care Association Conference
ADDISON, Texas, April 15, 2010 /PRNewswire via COMTEX/ -- ULURU Inc. (NYSE Amex: ULU) announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2010 SAWC/WHS meeting. In addition to the presentation of the clinical evidence, the Company will also be providing educational guidance, showcasing advanced research on Altrazeal(TM) and products in the Altrazeal(TM) pipeline.
Posters detailing application techniques and clinical care with Altrazeal(TM) in all major wound types, including diabetic foot, pressure and venous ulcers, will be presented to show how the product can be used in practice to treat these wounds.
Altrazeal(TM) has shown a statistically significant decrease in pain in a randomized controlled clinical study. This effect is further demonstrated in a case study detailing pain management in patients with venous ulcers, to be presented by Catherine T. Milne, APRN, MSN, BC-ANP, CWOCN of Connecticut Clinical Nursing Associates, LC Bristol Hospital Wound, Ostomy, Lymphedema Center Bristol, Connecticut. Ms. Milne stated, "Wound pain is a tremendous burden for these patients. Having found a topical, cost effective method to reduce pain enhances patient compliance in wound care."
Details of how to incorporate Altrazeal(TM) into the home healthcare practice, including patient selection and clinical protocols, will be demonstrated in a poster authored by Bobbie Spitz, RN CNS - BC CWS of the Aurora Visiting Nurse Association of Wisconsin in Milwaukee, Wisconsin. The poster titled, "Patient Selection and Incorporation of a Novel Transforming Powder Dressing in Home Healthcare" describes cost benefits and nursing time benefits to be derived using Altrazeal(TM) in certain patient populations.
A number of clinical posters by Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, explain multiple case studies where Altrazeal(TM) has been used successfully in difficult to heal wound types. Also, a poster describes how utilizing total contact casts with Altrazeal(TM) may shorten days to heal in neuropathic diabetic foot ulcers. Another poster will detail cases where techniques were developed to incorporate Altrazeal(TM) in the treatment of pressure ulcers, with pain and moisture management, in this difficult to treat class of wounds.
These poster presentations by Dr. Bohn follow his well-attended podium presentation at the American Professional Wound Care Association (APWCA) national conference on Saturday, April 10th. The presentation titled "Transforming Powder Wound Dressing Relieves Pain and Manages Moisture, Restoring Quality of Life" generated significant audience participation in a question and answer session following the presentation, generating very positive feedback on the attributes of Altrazeal(TM).
Renaat Van den Hooff, President and CEO of ULURU Inc., commented, "The clinical experience data that will be presented at the SAWC/WHS Symposium is compelling and highlights the clinical, pharma-economic and patient benefits that Altrazeal(TM) provides. This event comes only a week after a highly successful presentation of clinical evidence and Dr. Bohn's presentation at the APWCA conference. These meetings allow more and more clinicians to discover the benefits that Altrazeal(TM) provides."
ULURU will also present a poster detailing the preclinical and formulation development of Altrazeal Collagen, a new and important addition to the Altrazeal(TM) family of products.
A set of three advanced technology Altrazeal(TM) posters have also been accepted for presentation at the prestigious Wound Healing Society Blue Ribbon Poster contest. These posters include a technique for moisture management of living skin equivalent constructs when combined with Altrazeal, details surrounding the effectiveness and importance of intimate contact between Altrazeal(TM) Silver and tissue and a poster on an innovative Nanoflex(TM) technology advancement utilizing ULURU's gel formulation as a tunneling wound gel.
ULURU will also be present at the SAWC/WHS conference with a booth in the exhibit space to provide information on Altrazeal(TM) application techniques, best clinical experiences and the patient and economic benefits to be derived using Altrazeal(TM).
Information about SAWC/WHS and the annual spring meeting can be found at spring.sawc.net
ULU News:
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS)
Follows Highly Successful Oral Presentation at the 2010 American Professional Wound Care Association Conference
ADDISON, Texas, April 15, 2010 /PRNewswire via COMTEX/ -- ULURU Inc. (NYSE Amex: ULU) announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2010 SAWC/WHS meeting. In addition to the presentation of the clinical evidence, the Company will also be providing educational guidance, showcasing advanced research on Altrazeal(TM) and products in the Altrazeal(TM) pipeline.
Posters detailing application techniques and clinical care with Altrazeal(TM) in all major wound types, including diabetic foot, pressure and venous ulcers, will be presented to show how the product can be used in practice to treat these wounds.
Altrazeal(TM) has shown a statistically significant decrease in pain in a randomized controlled clinical study. This effect is further demonstrated in a case study detailing pain management in patients with venous ulcers, to be presented by Catherine T. Milne, APRN, MSN, BC-ANP, CWOCN of Connecticut Clinical Nursing Associates, LC Bristol Hospital Wound, Ostomy, Lymphedema Center Bristol, Connecticut. Ms. Milne stated, "Wound pain is a tremendous burden for these patients. Having found a topical, cost effective method to reduce pain enhances patient compliance in wound care."
Details of how to incorporate Altrazeal(TM) into the home healthcare practice, including patient selection and clinical protocols, will be demonstrated in a poster authored by Bobbie Spitz, RN CNS - BC CWS of the Aurora Visiting Nurse Association of Wisconsin in Milwaukee, Wisconsin. The poster titled, "Patient Selection and Incorporation of a Novel Transforming Powder Dressing in Home Healthcare" describes cost benefits and nursing time benefits to be derived using Altrazeal(TM) in certain patient populations.
A number of clinical posters by Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, explain multiple case studies where Altrazeal(TM) has been used successfully in difficult to heal wound types. Also, a poster describes how utilizing total contact casts with Altrazeal(TM) may shorten days to heal in neuropathic diabetic foot ulcers. Another poster will detail cases where techniques were developed to incorporate Altrazeal(TM) in the treatment of pressure ulcers, with pain and moisture management, in this difficult to treat class of wounds.
These poster presentations by Dr. Bohn follow his well-attended podium presentation at the American Professional Wound Care Association (APWCA) national conference on Saturday, April 10th. The presentation titled "Transforming Powder Wound Dressing Relieves Pain and Manages Moisture, Restoring Quality of Life" generated significant audience participation in a question and answer session following the presentation, generating very positive feedback on the attributes of Altrazeal(TM).
Renaat Van den Hooff, President and CEO of ULURU Inc., commented, "The clinical experience data that will be presented at the SAWC/WHS Symposium is compelling and highlights the clinical, pharma-economic and patient benefits that Altrazeal(TM) provides. This event comes only a week after a highly successful presentation of clinical evidence and Dr. Bohn's presentation at the APWCA conference. These meetings allow more and more clinicians to discover the benefits that Altrazeal(TM) provides."
ULURU will also present a poster detailing the preclinical and formulation development of Altrazeal Collagen, a new and important addition to the Altrazeal(TM) family of products.
A set of three advanced technology Altrazeal(TM) posters have also been accepted for presentation at the prestigious Wound Healing Society Blue Ribbon Poster contest. These posters include a technique for moisture management of living skin equivalent constructs when combined with Altrazeal, details surrounding the effectiveness and importance of intimate contact between Altrazeal(TM) Silver and tissue and a poster on an innovative Nanoflex(TM) technology advancement utilizing ULURU's gel formulation as a tunneling wound gel.
ULURU will also be present at the SAWC/WHS conference with a booth in the exhibit space to provide information on Altrazeal(TM) application techniques, best clinical experiences and the patient and economic benefits to be derived using Altrazeal(TM).
Information about SAWC/WHS and the annual spring meeting can be found at spring.sawc.net
Keep an eye on XSEL. Expect full 09 financials out by April 20th.
NBY positive phase 2 data:
NovaBay Pharmaceuticals Reports Positive Data From Exploratory Phase 2 Trial
NovaBay Pharmaceuticals Reports Positive Data From Exploratory Phase 2 Trial
Multi-Center Study Planned in Q3 for Lead Anti-Infective, NVC-422, in Urinary Catheter Blockage and Encrustation Apr. 15, 2010 (GlobeNewswire) --
EMERYVILLE, Calif., April 15, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.
Certain Gram-negative pathogens present in bacteriuria can cause urinary catheter blockage, a common occurrence among patients who are permanently catheterized. Urinary catheter blockage can often lead to catheter-associated urinary tract infections (CAUTI). Permanently catheterized patients include those suffering from conditions such as spinal cord injury, neurogenic bladder, spina bifida and multiple sclerosis.
"We are encouraged by the results of this study, both in terms of treatment tolerability and the activity against multiple uropathogens in patients with high levels of bacteriuria," said Dr. Behzad Khosrovi, senior vice president of product development. "We now look forward to initiating additional studies evaluating the use of advanced formulations of NVC-422 in preventing or reducing urinary catheter blockage and encrustation in permanently catheterized spinal cord injury patients."
Study Design and Results
Enrollment criteria included a condition requiring chronic transurethral catheterization for at least one month prior to enrollment, documented high levels of bacteriuria, and no treatment with antimicrobial agents during the preceding week. Following baseline urine cultures, 25 to 100mL of a sterile solution of NVC-422, depending on bladder capacity, was instilled through the catheter into the bladder. The drainage tube was clamped for 1 hour and then allowed to drain. Urine specimens were collected before and following each instillation and daily during post-treatment follow-up.
In the first part of the study, five patients were treated with a single administration of 0.1% NVC-422. The treatment was well tolerated and some transient antimicrobial activity was observed. In Part 2a of the study, five patients were treated with 0.1% NVC-422 daily for seven days; in Part 2b, five patients were treated with a higher NVC-422 concentration of 0.2% daily for seven days. No significant adverse events related to NVC-422 were observed.
Despite the presence of high urinary concentrations (greater than 100,000 colony-forming units per mL) of multiple uropathogens at baseline, a number of these were eradicated by the end of the treatment. These effects were more pronounced in subjects treated with the higher concentration of NVC-422.
NovaBay's lead Aganocide® compound, NVC-422, has broad-spectrum anti-microbial activity against bacteria tested, including uropathogens, bacteria resistant to antibiotics, and bacteria encased in biofilm. The use of NVC-422 solutions to control bacteria that inevitably and rapidly develop in urinary catheters and in the bladder represents a significant opportunity for NovaBay. These bacteria are increasingly resistant to antibiotics.
"The encouraging findings of this exploratory study lay the foundation for future investigation of the potential role of this class of non-antibiotic antimicrobials in controlling the consequences of catheter-associated bacteriuria," said Dr. Rabih O. Darouiche, the principal investigator of the study and a professor and director of the Center for Prostheses Infection at Baylor College of Medicine.
CAUTI is the most common type of hospital-acquired infection, accounting for approximately 30 percent of such infections and for most of the 900,000 patients with bacteriuria in U.S. hospitals annually.
NovaBay plans to initiate a multi-center Phase 2 trial of NVC-422 in the third quarter for the treatment of urinary catheter blockage and encrustation.
Conference Call Scheduled
On Monday, April 19, at 2 p.m. EDT, members of NovaBay's management team will host a conference call to discuss results of the trial and to provide a pipeline update of its development programs. To join the audio conference and participate in the Q&A session, please call 1-800-434-1335 (outside the U.S., dial 1-404-920-6442), and provide the operator with code 353316.
Live audio of the conference call will be broadcast simultaneously over the internet. Please pre-register for the call at: http://tinyurl.com/novapharmreg. Once the registration process is complete, you will receive a confirmation e-mail with instructions on how to join the conference.
A replay of the webcast will be available shortly after the call and may be accessed via NovaBay's website: www.novabaypharma.com.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a license and research collaboration agreement with Alcon, Inc. for use of NovaBay's Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize NovaBay's Aganocide compounds in acne, impetigo and other dermatological indications. For more information visit www.novabaypharma.com.
Be interesting to see how tomorrow goes. Did you ever get in at all?
Log off and give others a chance. LOL
Yeah, Alive, other day when you and I talked about EFIR, I nearly gave up the next couple days. But, today I was glad I hadn't given up. Lookin good....now for the 10k to come out.
WEEEEEEEEEEEEEEEEEEEEE
Based on the filings, they are supposed to bring it out within 15 days of its due date. The due date from my understanding was March 31, so tomorrow seems to be the date to expect the filing to be released.
EFIR expecting 10k by close tomorrow according to NT filing out yesterday. Today's action would make one think good things are coming. GLTY
Great movement here today bird. Hoping for solid 10k tomorrow to push this puppy even higher.